Zymeworks Price to Book Ratio 2016-2021 | ZYME

Historical price to book ratio values for Zymeworks (ZYME) over the last 10 years. The current price to book ratio for Zymeworks as of December 07, 2021 is 3.05.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Zymeworks Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
2021-12-06 18.22 3.04
2021-09-30 29.04 $5.99 4.85
2021-06-30 34.69 $6.95 4.99
2021-03-31 31.58 $8.17 3.87
2020-12-31 47.26 $8.90 5.31
2020-09-30 46.58 $9.44 4.93
2020-06-30 36.07 $10.78 3.35
2020-03-31 35.47 $11.47 3.09
2019-12-31 45.46 $6.21 7.32
2019-09-30 24.80 $7.87 3.15
2019-06-30 22.00 $8.53 2.58
2019-03-31 16.18 $5.30 3.05
2018-12-31 14.68 $5.64 2.60
2018-09-30 15.70 $5.31 2.96
2018-06-30 14.78 $5.84 2.53
2018-03-31 12.02 $3.71 3.24
2017-12-31 7.59 $4.58 1.66
2017-09-30 7.98 $3.26 2.45
2017-06-30 8.35 $3.83 2.18
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.850B $0.039B
Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $126.808B 8.01
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.211B 20.68
Biohaven Pharmaceutical Holding (BHVN) United States $6.887B 0.00
Arcus Biosciences (RCUS) United States $3.210B 0.00
Emergent Biosolutions (EBS) United States $2.270B 8.16
Myovant Sciences (MYOV) United Kingdom $1.508B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.469B 0.00
SQZ Biotechnologies (SQZ) United States $0.326B 0.00
Ambrx Biopharma (AMAM) United States $0.322B 0.00
Enzo Biochem (ENZ) United States $0.170B 16.71